Resources
AVAC’s Resource Database contains educational and advocacy materials covering a wide range of issues on biomedical prevention of HIV, STIs, COVID-19 and emerging health threats—from research to rollout.
To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database
Results
showing 1-10 of 888
Statement of Solidarity with the Nigerian Key Population Community on the Murder of their Leader, Christopher Ikpu Terfa: A Call for unity, solidarity, and government protection
6 August 2024 The Key Population Consortia Transnational Collaboration (KP-TNC) stands in solidarity with the Nigeria Key Population Health Rights Network (KP-HRN), Nigeria’s KP leadership and community, and the global KP community as we...
PxPulse: An Advocacy Chronicle on U=U in South Africa with Mandisa Dukashe
Mandisa Tyadi Dukashe, Treatment Technical Lead at the South African National AIDS Council (SANAC) describes her work in helping to inspire and launch a National U=U Campaign in South Africa in 2024.
Prevention Option:
Years Ahead in HIV Prevention Research: Time to Market
This timeline shows the potential time points when the next-generation of HIV prevention options might find their way into new programs.
Prevention Option:
Pandemic Accord Priority for 2025
As members of the Coalition of Advocates for Global Health and Pandemic Preparedness, a group of organizations advocating for an integrated and holistic approach to preparedness that emphasizes equity, inclusion, and synergies of multiple global health programs in advancing preparedness, we share the following asks with regard to the ongoing Pandemic Accord negotiations after their extension past May 2024.
Prevention Option:
PrEP Initiations by Country Worldwide
AVAC tracks global PrEP use by conducting quarterly surveys of ongoing oral PrEP demonstration and implementation projects, and collecting data from manufacturers and government agencies. This graphic shows data on PrEP initiations around the globe.
Prevention Option:
Harnessing private sector strategies for family planning to deliver the Dual Prevention Pill, the first multipurpose prevention technology with pre-exposure prophylaxis, in an expanding HIV prevention landscape
Working with colleagues, AVACers Cat Verde Hashim and Kate Segal published this research article in the Journal of the International AIDS Society. The researchers undertook qualitative research in Kenya, South Africa and Zimbabwe to prioritize private sector service delivery approaches for the introduction of the DPP.
Prevention Option:
PxWire Volume 14, Issue No. 3
In addition to an update on the PrEP pipeline, this issue of PxWire discusses the impact of policies on PrEP uptake, contrasting Uganda’s disastrous Anti-Homosexuality Act with the positive impact of other countries’ comprehensive anti-discrimination policies.
Prevention Option:
Generic Cabotegravir Timelines
As CAB for PrEP is a long-acting, extended-release injection, bioequivalence (BE) testing takes time to determine whether the generic drug functions in the body similarly to the original drug. As shown in this timeline graphic, the BE study (as determined by WHO guidance) is the longest part of the development process for generic CAB. But other steps, such as selecting and licensing generic manufacturers and technology transfer could be done faster.
Prevention Option:
What Happens to PrEP Initiations in Countries with Anti-Discrimination Policies?
Among 134 countries reviewed, 42 have comprehensive anti-discrimination policies covering a broad range of populations, while 24 lack any such policies. The remaining countries have adopted partial measures. Nations with comprehensive anti-discrimination policies, document significantly higher rates of PrEP initiation compared to those without such protections.
Prevention Option:
Impact of the Anti-Homosexuality Act on PrEP Uptake Rates in Uganda Compared to Other Countries
Oral PrEP initiations in Uganda were among the highest in the region, with sizable increases each quarter, until the enactment of the Anti-Homosexuality Act (AHA) in March 2023. Since then, the number of new PrEP initiations plummeted, and have since struggled to sustain rates seen in 2023. Public policies clearly matter.
showing 1-10 of 888